Androgen-independent prostate cancer progression in the TRAMP model - PubMed (original) (raw)

. 1997 Nov 1;57(21):4687-91.

Affiliations

PMID: 9354422

Androgen-independent prostate cancer progression in the TRAMP model

J R Gingrich et al. Cancer Res. 1997.

Abstract

We previously established the autochthonous transgenic adenocarcinoma mouse prostate (TRAMP) model to facilitate characterization of molecular mechanisms involved in the initiation and progression of prostate cancer. TRAMP mice display high grade prostatic intraepithelial neoplasia or well-differentiated prostate cancer by 10-12 weeks of age. To test the hypothesis that molecular events leading to androgen independence and metastasis can occur early in the natural history of prostate cancer yet remain silent until selective pressures such as androgen deprivation are applied, we have examined the consequences of castration on the initiation and progression to metastatic prostate cancer in TRAMP mice. Cohorts were castrated at 12 weeks of age and sacrificed at 18 (T12/18) or 24 (T12/24) weeks of age, and the development of primary cancer and metastatic disease was compared to noncastrated (T18 and T24) controls. Median T12/18 and T12/24 genitourinary (GU) weight was significantly less than T18 and T24, respectively. In addition, T12/24 GU weight was significantly greater than T12/18. Histological prostate tumors developed in 3 of 7 T12/18 and 8 of 10 T12/24 mice. All tumors that developed in castrated mice were poorly differentiated in contrast to 27% in noncastrated controls. Although castration significantly decreased GU tumor burden, overall progression to poorly differentiated and metastatic disease was not ultimately delayed. These results demonstrate that prostate cancer in the TRAMP model is heterogeneous with respect to androgen dependence as early as 12 weeks of age; therefore, early androgen ablation may have a variable impact on progression in an individual mouse. Further analysis of this prostate cancer model to identify specific molecular mechanisms that determine androgen sensitivity may facilitate future initiation of appropriate individualized hormonal therapy for the management of human prostate cancer.

PubMed Disclaimer

Cited by

Development of animal models underlining mechanistic connections between prostate inflammation and cancer.
Mimeault M, Batra SK. Mimeault M, et al. World J Clin Oncol. 2013 Feb 10;4(1):4-13. doi: 10.5306/wjco.v4.i1.4. World J Clin Oncol. 2013. PMID: 23539141 Free PMC article.
Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells.
Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K, Shirai T. Tang M, et al. Cancer Sci. 2007 Apr;98(4):471-7. doi: 10.1111/j.1349-7006.2007.00417.x. Epub 2007 Jan 31. Cancer Sci. 2007. PMID: 17284254 Free PMC article.
Vitamin D metabolism and action in the prostate: implications for health and disease.
Swami S, Krishnan AV, Feldman D. Swami S, et al. Mol Cell Endocrinol. 2011 Dec 5;347(1-2):61-9. doi: 10.1016/j.mce.2011.05.010. Epub 2011 Jun 1. Mol Cell Endocrinol. 2011. PMID: 21664249 Free PMC article. Review.
A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells.
Garabedian EM, Humphrey PA, Gordon JI. Garabedian EM, et al. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15382-7. doi: 10.1073/pnas.95.26.15382. Proc Natl Acad Sci U S A. 1998. PMID: 9860977 Free PMC article.
Dietary flavonoid fisetin increases abundance of high-molecular-mass hyaluronan conferring resistance to prostate oncogenesis.
Lall RK, Syed DN, Khan MI, Adhami VM, Gong Y, Lucey JA, Mukhtar H. Lall RK, et al. Carcinogenesis. 2016 Sep;37(9):918-928. doi: 10.1093/carcin/bgw071. Epub 2016 Jun 22. Carcinogenesis. 2016. PMID: 27335141 Free PMC article.

Androgen-independent prostate cancer progression in the TRAMP model - PubMed (original) (raw)